SHILPAMED.NSSHILPAMED.NSNSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +11.46% | +13.59% | +9.90% | +7.61% | +28.31% |
| Gross Profit Growth | +20.19% | +123.99% | +140.76% | +19.23% | -28.79% |
| EBITDA Growth | +21.95% | -16.88% | +22.33% | +21.31% | +24.97% |
| Operating Income Growth | +31.29% | +10.43% | +34.90% | +35.92% | +61.78% |
| Net Income Growth | +593.89% | -40.79% | +233.42% | +145.67% | +40.27% |
| EPS Growth | +513.21% | -47.52% | +228.77% | +145.90% | +40.31% |
| EPS Diluted Growth | +513.21% | -47.52% | +228.77% | +145.90% | +40.31% |
| Weighted Average Shares Growth | +13.16% | +12.19% | +1.63% | -0.23% | -0.01% |
| Weighted Average Shares Diluted Growth | +13.16% | +12.19% | +1.63% | -0.23% | -0.01% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +12.45% | +0.00% | +18.63% | +0.00% |
| Inventory Growth | +0.00% | +0.87% | +0.00% | +36.23% | +0.00% |
| Asset Growth | +0.00% | +7.03% | +0.00% | +12.12% | +0.00% |
| Book Value per Share Growth | +15.49% | +16.91% | +29.22% | +4.94% | +0.00% |
| Debt Growth | +0.00% | -37.30% | +0.00% | +20.93% | +0.00% |
| R&D Expense Growth | +0.00% | +56.20% | +0.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | -100.00% | +22.09% | -100.00% | +0.00% | +0.00% |